The responses to treatments were evaluated every 2 months or suspected disease
progression. Pelvic examination and plasma tumor markers were routinely
performed each time. Imaging tests including computed tomography (CT), positron
emission tomography-computed tomography (PET-CT), single-photon emission
computed tomography (SPECT), and magnetic resonance imaging (MRI) were used as
appropriate to determine the size of tumors. The Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1 was used to determine CR, PR, stable disease
(SD), or progressive disease (PD). During the nontreatment period, follow-up was
performed every 3 months until death or the patient was censored. Disease-free
survival (DFS) was defined as the period from the date of surgery to the
diagnosis of first recurrence/metastasis, and OS was defined as the period from
the beginning of treatment after first recurrence/metastasis to the death, with
patients alive at last follow-up censored on that date. PFS was defined as the
period from the treatment beginning after first recurrence/metastasis to the
second recurrence/metastasis or death, with patients censored if alive and with
no evidence of tumor recurrence/metastasis.